Oxygenta Pharmaceutical Financial Statements
Oxygenta Pharmaceutical financial statements. In FYNone, Oxygenta Pharmaceutical (OXYGENTAPH) reported revenue ₹113 Cr, net profit ₹-17 Cr and EPS ₹-2.50, with a net profit margin of -9.0%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Analyse OXYGENTAPH FII DII holdings to track promoter, FII and institutional holdings.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
OXYGENTAPH Revenue, Net Profit & EBITDA — Year-on-Year Growth
OXYGENTAPH YoY (March 2025 vs Period) — revenue +1.8%, net profit -70.0%, EBITDA -88.9%, expenses +9.2%. Read OXYGENTAPH dividend history for the complete payout history and dividend yield track record.
OXYGENTAPH Income Statement — Revenue, EBITDA & Net Profit
Oxygenta Pharmaceutical revenue ₹113 Cr, EBITDA ₹-17 Cr, net profit ₹-17 Cr, EPS ₹-2.50 (None) — net profit margin -9.0%. For live price, earnings ratios and company overview, see Oxygenta Pharmaceutical share price today.
| Particulars | None | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113 | 111 | 40 | 31 | 61 | 52 | 14 | 21 | 14 | 9 | 12 | 6 |
| Expenses | 130 | 119 | 49 | 38 | 59 | 48 | 22 | 23 | 17 | 13 | 17 | 10 |
| EBITDA | -17 | -9 | -10 | -7 | 2 | 4 | -8 | -2 | -3 | -4 | -4 | -4 |
| Operating Profit Margin % | -24.00% | -9.00% | -24.00% | -23.00% | 2.00% | 7.00% | -57.00% | -10.00% | -31.00% | -59.00% | -34.00% | -66.00% |
| Depreciation | 2 | 1 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Interest | 4 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
| Profit Before Tax | -23 | -12 | -14 | -11 | -1 | 3 | -6 | -4 | -5 | -6 | -6 | -7 |
| Tax | 0 | -2 | -10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Net Profit | -17 | -10 | -4 | -12 | -1 | 3 | -6 | -3 | -5 | -6 | -6 | -6 |
| Earnings Per Share (₹) | -2.50 | -2.69 | -1.09 | -8.15 | -0.48 | 2.87 | -5.67 | -3.19 | -4.44 | -5.69 | -5.39 | -5.99 |
OXYGENTAPH Balance Sheet — Assets, Liabilities & Shareholders' Equity
OXYGENTAPH total assets ₹83 Cr, total equity ₹-25 Cr, total liabilities ₹83 Cr (2025).
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Total Assets | 83 | 63 | 54 | 31 | 34 | 19 | 21 | 17 | 19 | 20 | 18 |
| Current Assets | 31 | 24 | 25 | 10 | 16 | 7 | 9 | 4 | 6 | 5 | 5 |
| Fixed Assets | 40 | 29 | 28 | 20 | 16 | 11 | 12 | 12 | 12 | 13 | 12 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 44 | 34 | 26 | 11 | 17 | 7 | 9 | 5 | 6 | 7 | 7 |
| LIABILITIES | |||||||||||
| Total Liabilities | 83 | 63 | 54 | 31 | 34 | 19 | 21 | 17 | 19 | 20 | 18 |
| Current Liabilities | 23 | 50 | 68 | 58 | 54 | 43 | 38 | 29 | 29 | 21 | 19 |
| Non-Current Liabilities | |||||||||||
| SHAREHOLDERS' EQUITY | |||||||||||
| Total Equity | -25 | -20 | -46 | -35 | -38 | -41 | -35 | -32 | -27 | -22 | -16 |
| Share Capital | 37 | 34 | 14 | 14 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | -62 | -54 | -60 | -49 | -48 | -51 | -45 | -42 | -38 | -32 | -26 |
OXYGENTAPH Cash Flow Statement — Operating, Investing & Financing
Oxygenta Pharmaceutical operating cash flow ₹3 Cr, investing ₹-11 Cr, financing ₹9 Cr, net cash flow ₹0 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 | March 2018 | March 2017 | March 2016 | March 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3 | -13 | -2 | -2 | -2 | -3 | -8 | 1 | 1 | 1 | -4 |
| Investing Activities | -11 | -4 | -10 | -5 | -7 | -1 | -1 | 0 | -1 | -2 | 1 |
| Financing Activities | 9 | 17 | 11 | 6 | 9 | 3 | 8 | -1 | 0 | 1 | 3 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |